Epizyme to Participate in Two Upcoming Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, Inc., a company leading the discovery and development of targeted therapeutics for genetically-defined cancer patients based on breakthroughs in the field of epigenetics, today announced its participation in two upcoming conferences. Robert Gould, Ph.D., President and CEO, will present at the Alexandria Summit on Oncology, held April 14-15 in New York City. Jason P. Rhodes, EVP and Chief Business Officer, will present at the 18th Annual Future Leaders in the Biotech Industry conference, hosted by BioCentury and Thomson Reuters at the Millennium Broadway Hotel in New York City on April 15, from 2:30-3:00pm in breakout room 401.

Epizyme’s therapeutics discovery programs are focused on histone methyltransferases (HMTs), a class of epigenetic enzymes that play an important role in regulating pathways of genes that are strongly associated with the underlying causes of many human diseases, including cancer. Epizyme announced a program-based partnership with Eisai for the epigenetic enzyme EZH2 in March 2011 and a multi-target drug discovery alliance with GlaxoSmithKline in January 2011.

About Epizyme

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. www.epizyme.com


MacDougall Biomedical Communications
Jennifer Conrad or Chris Erdman, 781-235-3060

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Pharmaceutical



Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.